^
Association details:
| Biomarker: | ERCC5 overexpression |
|---|---|
| Cancer: | Sarcoma |
| Drug: | doxorubicin hydrochloride (Topoisomerase II inhibitor) + Yondelis (trabectedin) (Alkylating agent, DNA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CUL4A, ERCC5, and ERCC1 as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study
Published date:
04/30/2020
Excerpt:
In the group treated with trabectedin plus doxorubicin, the median of PFS was significantly longer in cases with CUL4A, ERCC1, or ERCC5 overexpression...CUL4A, ERCC5, and mainly ERCC1 acted as predictive factors for trabectedin efficacy in advanced STS.
DOI:
10.3390/cancers12051128
